Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | LGALS3 | P17931 | 3/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.46 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.46 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4169921 | 1.00 | CA2 (0.52) | CA2CA9CA1LGALS3LGALS8 | |
| SCHEMBL9231724 | 0.83 | CA2 (0.51) | CA2CA9CA1LGALS3LGALS8 | |
| SCHEMBL9231731 | 0.83 | CA2 (0.51) | CA2CA9CA1LGALS3LGALS8 | |
| SCHEMBL14134617 | 0.83 | CA2 (0.51) | CA2CA9CA1LGALS8 | |
| SCHEMBL12081984 | 0.83 | CA2 (0.51) | CA2CA9CA1LGALS8 | |
| SCHEMBL12085042 | 0.83 | CA2 (0.51) | CA2CA9CA1LGALS8 | |
| SCHEMBL12085043 | 0.81 | LGALS8 (0.51) | CA2CA9CA1LGALS8 | |
| SCHEMBL4114206 | 0.81 | LGALS8 (0.51) | CA2CA9CA1LGALS8 | |
| SCHEMBL12082304 | 0.81 | LGALS8 (0.51) | CA2CA9CA1LGALS8 | |
| SCHEMBL14134610 | 0.81 | CA2 (0.51) | CA2CA9CA1LGALS8POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163697-A1 | Multicomponent coupling and glycopeptide synthesis with cyclic thioanhydrides | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163697-A1 | Multicomponent coupling and glycopeptide synthesis with cyclic thioanhydrides | LNPEP, CLSPN, GALNT14 | CA2 2265/4885CA9 1568/4885CA1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.